Inclusion Complexation and Solubilization of Paclitaxel by Bridged Bis(β-cyclodextrin)s Containing a Tetraethylenepentaamino Spacer

Journal of Medicinal Chemistry

Volumn 46, Issue 22, 2003, Pages 4634-4637

  Liu, Yu ^a   Chen, Guo Song ^a   Li, Li ^a   Zhang, Heng Yi ^a   Cao, Dong Xu ^b   Yuan, Ying Jin ^b  

^a NANKAI UNIVERSITY   (China)

^b TIANJIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL DERIVATIVE; PACLITAXEL TETRAETHYLENEPENTAAMINO BIS(BETA CYCLODEXTRIN); UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACTIVITY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FOURIER TRANSFORMATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTON NUCLEAR MAGNETIC RESONANCE; SCANNING ELECTRON MICROSCOPY; THERMOGRAVIMETRY; X RAY POWDER DIFFRACTION;

ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CALORIMETRY, DIFFERENTIAL SCANNING; CYCLODEXTRINS; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, SCANNING; MODELS, MOLECULAR; PACLITAXEL; POLYAMINES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMOGRAVIMETRY; X-RAY DIFFRACTION;

EID: 0142124208     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm034148f     Document Type: Article

References (30)

1. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus brevifolia. J. Am. Chem. Soc. 1971, 93, 2325-2327.
2. (a) Ding, A. H.; Porteu, F.; Sanchez, E.; Nathan, C. F. Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 1990, 248, 370-372.
3. (b) Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277, 665-667.
4. (a) Swindell, C. S.; Krauss, N. E.; Horwitz, S. B.; Ringel, I. Biologically active taxol analogs with deleted A-ring side chain substituents and variable C-2′ configurations. J. Med. Chem. 1991, 34, 1176-1184.
5. (b) Mathew, A. E.; Mejillano, M. R.; Nath, J. P.; Himes, R. H.; Stella, V. J. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J. Med. Chem. 1992, 35, 145-151.
6. (c) Tarr, B. D.; Yalkowsky, S. H. A new parenteral vehicle for the administration of some poorly water soluble anti-cancer drugs. J. Parent. Sci. Technol. 1987, 41, 31-33.
7. (a) Li, J.-L.; Feng, X.; Liu, B.; Yuan, Y.-J. Recent studies on taxol related water-soluble prodrugs. Chin. J. Org. Chem. 2001, 21, 428-435.
8. (b) Wrasidlo, W.; Gaedicke, G.; Guy, R. K.; Renaud, J.; Pitsinos, E.; Nicolaou, K. C.; Reisfeld, R. A.; Lode, H. N. A novel 2′ -(N-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models. Bioconjugate Chem. 2002, 13, 1093-1099.
9. (c) Niethammer, A.; Gaedicke, G.; Lode, H. N.; Wrasidlo, W. Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility. Bioconjugate Chem. 2001, 12, 414-420.
10. Colin, M.; Guenard, D.; Gueritte-Voegelein, F.; Potier, P. Taxol derivatives, their preparation and pharmaceutical compositions containing them. US Pat. 4814470, 1989.
11. Jagtap, P. G.; Baloglu, E.; Barron, D. M.; Bane, S.; Kingston, D. G. I. Design and synthesis of a combinatorial chemistry library of 7-acyl, 10-acyl, and 7, 10-diacyl analogues of paclitaxel (taxol) using solid-phase synthesis. J. Nat. Prod. 2002, 65, 1136-1142.
12. Adams, J. D.; Flora, K. P.; Goldspiel, B. R.; Wilson, J. W.; Finley, R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J. Natl. Cancer Inst. Monogr. 1993, 15, 141-147.
13. (a) Szente, L.; Szejili, J.; Vikmon, A. Inclusion complexes of taxol or taxotere or taxus extract formed with cyclodextins, its preparation and use. PCT Int. Appl. WO 9426728 A1, 1994.
14. (b) Szente, L.; Szejili, J.; Vikmon, A.; Szemán, J. Novel complexes and their compositions. PCT Int. Appl. WO 9614872 A1, 1996.
15. (c) Rubinfeld, J. Improved pharmaceutical formulation. PCT Int. Appl. WO 9506485 A1, 1995.
16. (d) Szente, L.; Szejtli, J.; Vikmon, A. Inclusion complexes of taxol or taxotere or taxus extract formed with cyclodextrins, its preparation and use. US Pat. 6284746, 2001.
17. (e) Lee, S.; Seo, D.; Kim, H.-W.; Jung, S. Investigation of inclusion complexation of paclitaxel by cyclohenicosakis-(1→2)-(β -D-glucopyranosyl), by cyclic-(1→2)-D-glucans (cyclosophoraoses), and by cyclomaltoheptaoses (β-cyclodextrins). Carbohydr. Res. 2001, 334, 119-126.
18. Szejtli, J. Introduction and general overview of cyclodextrin chemistry. Chem. Rev. 1998, 98, 1743-1754.
19. (a) Stella, V. J.; Rajewaki, R. A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 1997, 14, 556-567.
20. (b) Park, C. W.; Kim, S. J.; Park, S. J.; Kim, J. H.; Kim, J. K.; Park, G. B.; Kim, J. O.; Ha, Y. L. Inclusion complex of conjugated linoleic acid (CLA) with cyclodextrins. J. Argic. Food Chem. 2002, 50, 2977-2983.
21. (c) Montassier, P.; Duchêne, D.; Poelman, M.-C. Inclusion complexes of tretinoin with cyclodextrins. Int. J. Pharm. 1997, 153, 199-209.
22. (d) Arias-Blanco, M. J.; Moyano, J. R.; Perez-Martinez, J. I.; Gines, J. M. Study of the inclusion of gliclazide in α-cyclodextrin. J. Pharm. Biomed. Anal. 1998, 18, 275-279.
23. (e) Bodor; Nicholas, S. Pharmaceutical formulations for parenteral use. US Pat. 5024998, 1991.
24. Sharma, U. S.; Balasubramanian, S. V.; Straubinger, R. M. Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins. J. Pharm. Sci. 1995, 84, 1223-1230.
25. Moser, J. G.; Rose, I.; Wagner, B.; Wieneke, T.; Vervoorts, A. Taxol inclusion complexes with a cyclodextrin dimer: possibilities to detoxify chemotherapeutics and to target drugs specifically to tumors? J. Incl. Phenom. Mol. Recogn. 2001, 39, 13-18.
26. Liu, Y.; You, C.-C.; Li, B. Synthesis and molecular recognition of novel oligo(ethlenediamino) bridged bis(β-cyclodextrin)s and their copper(II) complexes: enhanced molecular binding ability and selectivity by multiple recognition. Chem. Eur. J. 2001, 7, 1281-1288.
27. 2 of TPCD, paclitaxel protons), δ 0.78-1.88 (m, 26H, paclitaxel protons).
28. Loftsson, T.; Brewster, M. E. Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization. J. Pharm. Sci. 1996, 85, 1017-1025.
29. 4/mL and treated with the indicated amounts of the complex.
30. Measurement of cytotoxicity: the effect of the complex was evaluated as cell survival after treatment. Cell viability was evaluated by a microculture tetrazolium reduction assay using MTT (3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma). Briefly, 50 mL of MTT stock solution (2 mg/mL in PBS) was added to 150 mL cell cultures in 96-microwell flat-bottom plates for 4 h incubation at 37 °C. Plates were then centrifuged, and MTT-containing culture medium was removed. Precipitated formazan was dissolved in 150 mL of DMSO. Results were read with 15 min in a spectrometer at 577 nm, and the means of triplicates were calculated. Cell inhibition rate is expressed as percentage of control samples.